NeuroSense Therapeutics Ltd. NRSN

NRSN Company Overview

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on the development of novel disease-modifying therapies for neurodegenerative diseases, with a primary emphasis on amyotrophic lateral sclerosis (ALS). The company operates within the biopharmaceutical and neuroscience therapeutics industries and is publicly traded on the Nasdaq Capital Market under the ticker NRSN. Its core mission is to address conditions with significant unmet medical needs through combination therapies that target multiple disease mechanisms simultaneously.

The company’s lead product candidate, PrimeC, is designed as a proprietary extended-release oral formulation combining two existing FDA-approved drugs intended to modulate complementary pathological pathways associated with ALS, including neuroinflammation and neurodegeneration. NeuroSense was founded in Israel and has evolved from preclinical research into a late clinical-stage company, advancing PrimeC through multi-country clinical trials while positioning itself for potential regulatory engagement in major pharmaceutical markets.